Table 2. The association between eight-lncRNA signature and OS of NSCLC patients in discovery and validating groups.
| Variable | Discovery Group | Validation Group-1 | Validation Group-2 | ||||||||
| Number (High/Low) |
HR (95%CI) | P value | Number (High/Low) |
HR (95%CI) | P value | Number (High/Low) |
HR (95%CI) | P value | |||
| Total | 228/228 | 2.08 (1.66-2.62) | <0.001 | 335/335 | 1.48 (1.17-1.86) | 0.001 | 65/65 | 2.96 (1.28-6.83) | 0.017 | ||
| Gender | |||||||||||
| Male | 171/142 | 1.89(1.46-2.45) | <0.001 | 209/212 | 1.46 (1.10-1.94) | 0.008 | 35/25 | 5.68 (1.41-11.47) | 0.010 | ||
| Female | 57/86 | 2.34 (1.53-3.96) | <0.001 | 126/123 | 1.55 (1.03-2.34) | 0.036 | 30/40 | 1.23 (0.31-4.96) | 0.772 | ||
| Smoking history | |||||||||||
| Never smoker | 1/16 | 4.60 (0.49-1458) | 0.117 | 22/29 | 1.74(0.72-4.17) | 0.189 | 24/42 | 1.75(0.43-7.65) | 0.420 | ||
| Ever smoker | 10/61 | 0.96 (0.34-2.70) | 0.934 | 217/237 | 1.382(1.03-1.85) | 0.029 | 41/22 | 3.889(0.98-8.38) | 0.055 | ||
| Current smoker | 8/40 | 1.11 (0.45-3.10) | 0.786 | 84/59 | 1.52(0.97-2.36) | 0.060 | 0/0 | NA | NA | ||
| Histology | |||||||||||
| Squamous Carcinoma | 141/95 | 2.04 (1.30-2.86) | 0.001 | 219/196 | 1.27 (0.96-1.70) | 0.099 | 0/0 | NA | NA | ||
| Adenocarcinoma | 68/152 | 2.11 (1.60-3.54) | <0.001 | 116/139 | 1.97 (1.32-2.95) | <0.001 | 0/0 | NA | NA | ||
| AJCC stage | |||||||||||
| Stage I | 144/166 | 2.12 (1.63-2.88) | < 0.001 | 180/174 | 1.68 (1.19-2.38) | 0.003 | 41/56 | 4.39 (1.32-13.25) | 0.015 | ||
| Stage II | 39/50 | 1.49 (0.88-2.57) | 0.138 | 97/86 | 1.44 (0.91-2.28) | 0.118 | 24/9 | 1.29 (0.37-4.37) | 0.703 | ||
| Stage III | 37/9 | 1.84 (0.94-3.31) | 0.087 | 54/57 | 1.25 (0.76-2.06) | 0.382 | 0/0 | NA | NA | ||
| Stage IV | 5/3 | 1.08 (0.22-5.44) | 0.925 | 3/13 | 6.02 (0.52-70.04) | 0.003 | 0/0 | NA | NA | ||
Abbreviations: HR, Hazard ratio; 95%CI, 95% confidence interval; AJCC, the American Joint Committee on Cancer.